

Press Release

EU multiannual financial framework funding for critical medicines manufacturing vital for strategic autonomy

Brussels, 20 March 2025

The EU Critical Medicines Act is essential for the security of supply of medicines. However, the Act can only achieve its goals of reducing shortages and increasing strategic autonomy with sufficient funding for manufacturing in Europe.

This funding should be made available through different sources including state aid dedicated EU critical medicines manufacturing fund in the future Multiannual Financial Framework (EU Budget), and regional aid.

Medicines for Europe commends the Parliament's Public Health Committee for its recommendation in the final opinion on the "Report on a revamped long-term budget for the Union in a changing world (2024/2051(INI))", to include dedicated EU critical medicines manufacturing funds in the future Multiannual Financial Framework (EU Budget). If combined with more flexible state aid and regional aid rules, this fund will drive a new wave of manufacturing investments in Europe.

We now call on the European Parliament's Committee on Budgets to include a proper space for health and critical medicines in their final report. Considering the strained geopolitical situation and the need for open strategic autonomy, Europe's supply of critical medicines must be secured.

About Medicines for Europe

Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information, please follow us at www.medicinesforeurope.com and on LinkedIn and X @medicinesforEU.